Abstract:120 Background: Prior studies have shown that exposure to concomitant medications such as metformin and statins influences survival in metastatic castrate resistant prostate cancer treated with androgen receptor pathway inhibitors (ARPI). However, it is unclear if such exposure to concomitant medications influences treatment response and survival in metastatic hormone sensitive prostate cancer (mHSPC) treated with ARPI. Methods: We performed a secondary analysis of the LATITUDE trial to determine whether exposure to concomitant medications influenced the effect from abiraterone, in addition to ADT, on overall survival (OS) and prostate cancer specific mortality (PCSM) in men with de novo high risk mHSPC. We focused on 7 commonly prescribed classes of medications: metformin, statins, proton pump inhibitors, cyclooxygenase 2 (COX-2) inhibitors, aspirin, acetaminophen, and NSAIDs (nonselective COX inhibitors except aspirin). To identify effect modification, we applied Cox regression models for OS with an interaction term between the medication classes and the randomized treatment regimen. To determine the independent association of each medication with OS and PCSM, we applied separate multivariable Cox regression and competing risk regression models, respectively. To account for multiple testing, 2-sided p<0.0024 was set as the threshold for statistical significance. Results: Overall, 1135 men were eligible. There was a non-significant evidence of differential effect from abiraterone on OS among men with concomitant exposure to aspirin (Hazard ratio [HR]: 0.93; 95% CI: 0.63-1.36) vs. those who did not (HR: 0.61 [0.51-0.73]) (interaction p=0.04). Similarly, there was a non-significant evidence of a differential effect from abiraterone on OS among men exposed to NSAIDs (HR: 0.54 [0.42-0.70]) vs. those who did not (HR: 0.74 [0.60-0.91]) (interaction p=0.05). Exposure to concurrent NSAIDs was associated with a significantly inferior OS (HR: 1.37 [1.15-1.62]; p<0.001) and higher relative incidence of PCSM (subdistribution HR: 1.47 [1.21-1.78]; p<0.001) in the overall cohort. There was a significantly higher relative excess risk of grade ≥3 cardiovascular adverse events by interaction of concomitant exposure to aspirin with abiraterone (RERI: 3.39 [0.68-6.11]). Conclusions: In this secondary analysis, concomitant exposure to 7 classes of medications was not associated with any statistically significant modification of abiraterone effect on OS in de novo high risk mHSPC. Men who received concurrent NSAIDs had a higher risk of PCSM and inferior OS even after adjustment for skeletal metastases burden and pain score. The excess risk of serious cardiovascular adverse events by interaction of abiraterone and exposure to aspirin could be due to reverse causality due to underlying burden of cardiovascular comorbidity in the exposed group.

Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients with Hormone-Sensitive Prostate Cancer.

Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients with Hormone-Sensitive Prostate Cancer

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study

Association between Statin Use and Clinical Outcomes in Patients with De Novo Metastatic Prostate Cancer: A Propensity Score-weighted Analysis

Whether Statin Use Improves the Survival of Patients with Glioblastoma?

Statin Use Is Associated with Better Prognosis of Patients with Prostate Cancer after Definite Therapies: A Systematic Review and Meta-Analysis of Cohort Studies

The association of statin use with survival outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor targeted therapies (ART)

Statin use and mortality risk in Asian patients with prostate cancer receiving androgen deprivation therapy: A population‐based cohort study

Opposing impact of hypertension/diabetes following hormone therapy initiation and preexisting statins on castration resistant progression of nonmetastatic prostate cancer: a multicenter study

Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer

Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone

Incidence of prostate, colorectal and male breast cancers in relation with statins and testosterone replacement therapy: SEER-Medicare 2007-2015

Regular Statin Users and Colorectal Cancer (CRC) Prognosis.

Statin Use is Associated with Improved Prognosis of Colorectal Cancer in Taiwan.

Serum Testosterone Level Predicts the Effective Time of Androgen Deprivation Therapy in Metastatic Prostate Cancer Patients.

Statin Use and the Risk of Prostate Cancer Biochemical Recurrence Following Definitive Therapy: A Systematic Review and Meta-Analysis of Cohort Studies

The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis

Statin concentration in prostatic tissue is subtype- and dose-dependent

Circulating Lipid Profiles Associated With Resistance to Androgen Deprivation Therapy in Localized Prostate Cancer

Effect of concomitant medications on treatment response and survival in de novo metastatic prostate cancer: Secondary analysis of the LATITUDE study.

Cholesterol-Lowering Drugs and Advanced Prostate Cancer Incidence in A Large Us Cohort